Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Merck and Indian CDMO Aragen have signed a memorandum of understanding for the manufacturing and development of monoclonal antibodies, Merck said Friday.
CDMO Scorpius is delaying its public offering that was previously announced in March, the company said Friday. Scorpius still intends to sell 12,500,000 shares at $1 apiece.
NorthStar Medical Radioisotopes and Convergent Therapeutics are partnering to develop the radiopharma biotech’s lead asset, dubbed CONV01-α, which is being investigated for prostate cancer. NorthStar will manufacture CONV01-α, supply the isotope Ac-225 and help with R&D activities, according to a Tuesday release.
Radiopharma company Blue Earth Therapeutics is expanding its manufacturing agreement with Austrian manufacturer Seibersdorf Laboratories, according to a Tuesday release. Seibersdorf will now also manufacture Blue Earth’s actinium-225-based radioligand therapy.
Cell and gene therapy CDMO ViroCell Biologics has finished an
